Sirolimus and everolimus reduce albumin endocytosis in proximal tubule cells via an angiotensin II-dependent pathway

Transplant Immunology

Volumn 23, Issue 3, 2010, Pages 125-132

  Oroszlán, Melinda ^a   Bieri, Michael ^a   Ligeti, Nathalie ^a   Farkas, Anikó ^a   Meier, Bernhard ^a   Marti, Hans Peter ^b   Mohacsi, Paul ^a  

^a BERN UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Angiotensin; Everolimus; Proliferation signal inhibitors; Proteinuria; Sirolimus; Transplantation

Indexed keywords

ALBUMIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; CUBILIN; EVEROLIMUS; HOE 33342; LOSARTAN; MEGALIN; RAMIPRIL; RAPAMYCIN;

ARTICLE; CELL LINE; CONTROLLED STUDY; DOWN REGULATION; DRUG ACTIVITY; DRUG POTENTIATION; ENDOCYTOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOFLUORESCENCE; KIDNEY TUBULE CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; STAINING;

ALBUMINS; ANGIOTENSIN II; CELL LINE; DOWN-REGULATION; DRUG THERAPY, COMBINATION; ENDOCYTOSIS; EPITHELIAL CELLS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TUBULES, PROXIMAL; LDL-RECEPTOR RELATED PROTEIN 2; LOSARTAN; RAMIPRIL; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION; SIROLIMUS;

EID: 77953911869     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trim.2010.05.003     Document Type: Article

References (47)

1. Chapman J.R., Valantine H., Albanell J., Arns W.A., Campistol J.M., Eisen H., et al. Proliferation signal inhibitors in transplantation: questions at the cutting edge of everolimus therapy. Transplant Proc 2007, 39:2937-2950.
2. Eisen H., Kobashigawa J., Starling R.C., Valantine H., Mancini D. Improving outcomes in heart transplantation: the potential of proliferation signal inhibitors. Transplant Proc 2005, 37:4S-17S.
3. Zuckermann A., Manito N., Epailly E., Fiane A., Bara C., Delgado J.F., et al. Multidisciplinary insights on clinical guidance for the use of proliferation signal inhibitors in heart transplantation. J Heart Lung Transplant 2008, 27:141-149.
4. Diekmann F., Gutierrez-Dalmau A., Lopez S., Cofan F., Esforzado N., Ricart M.J., et al. Influence of sirolimus on proteinuria in de novo kidney transplantation with expanded criteria donors: comparison of two CNI-free protocols. Nephrol Dial Transplant 2007, 22:2316-2321.
5. Franco A.F., Martini D., Abensur H., Noronha I.L. Proteinuria in transplant patients associated with sirolimus. Transplant Proc 2007, 39:449-452.
6. Vogelbacher R., Wittmann S., Braun A., Daniel C., Hugo C. The mTOR inhibitor everolimus induces proteinuria and renal deterioration in the remnant kidney model in the rat. Transplantation 2007, 84:1492-1499.
7. Lorber M.I., Mulgaonkar S., Butt K.M., Elkhammas E., Mendez R., Rajagopalan P.R., et al. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study. Transplantation 2005, 80:244-252.
8. Aliabadi A.Z., Pohanka E., Seebacher G., Dunkler D., Kammerstatter D., Wolner E., et al. Development of proteinuria after switch to sirolimus-based immunosuppression in long-term cardiac transplant patients. Am J Transplant 2008, 8:854-861.
9. Pinheiro H.S., Amaro T.A., Braga A.M., Bastos M.G. Post-rapamycin proteinuria: incidence, evolution, and therapeutic handling at a single center. Transplant Proc 2006, 38:3476-3478.
10. Straathof-Galema L., Wetzels J.F., Dijkman H.B., Steenbergen E.J., Hilbrands L.B. Sirolimus-associated heavy proteinuria in a renal transplant recipient: evidence for a tubular mechanism. Am J Transplant 2006, 6:429-433.
11. Stephany B.R., Augustine J.J., Krishnamurthi V., Goldfarb D.A., Flechner S.M., Braun W.E., et al. Differences in proteinuria and graft function in de novo sirolimus-based vs. calcineurin inhibitor-based immunosuppression in live donor kidney transplantation. Transplantation 2006, 82:368-374.
12. Dittrich E., Schmaldienst S., Soleiman A., Horl W.H., Pohanka E. Rapamycin-associated post-transplantation glomerulonephritis and its remission after reintroduction of calcineurin-inhibitor therapy. Transpl Int 2004, 17:215-220.
13. Taal M.W., Brenner B.M. Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists. Kidney Int 2000, 57:1803-1817.
14. Toto R. Angiotensin II subtype 1 receptor blockers and renal function. Arch Intern Med 2001, 161:1492-1499.
15. Odabas A.R., Cetinkaya R., Selcuk Y., Bilen H. Effect of losartan treatment on the proteinuria in normotensive patients having proteinuria due to secondary amyloidosis. Ups J Med Sci 2001, 106:183-188.
16. Zhou A., Yu L., Li J., Zhang J., Wang H. Renal protective effects of blocking the intrarenal renin-angiotensin system: angiotensin II type I receptor antagonist compared with angiotensin-converting enzyme inhibitor. Hypertens Res 2000, 23:391-397.
17. Galle J. Reduction of proteinuria with angiotensin receptor blockers. Nat Clin Pract Cardiovasc Med 2008, 5(Suppl 1):S36-S43.
18. Moestrup S.K., Verroust P.J. Megalin- and cubilin-mediated endocytosis of protein-bound vitamins, lipids, and hormones in polarized epithelia. Annu Rev Nutr 2001, 21:407-428.
19. Gekle M. Renal tubule albumin transport. Annu Rev Physiol 2005, 67:573-594.
20. Christensen E.I., Birn H. Megalin and cubilin: multifunctional endocytic receptors. Nat Rev Mol Cell Biol 2002, 3:256-266.
21. Moestrup S.K., Kozyraki R. Cubilin, a high-density lipoprotein receptor. Curr Opin Lipidol 2000, 11:133-140.
22. Leheste J.R., Rolinski B., Vorum H., Hilpert J., Nykjaer A., Jacobsen C., et al. Megalin knockout mice as an animal model of low molecular weight proteinuria. Am J Pathol 1999, 155:1361-1370.
23. Kantarci S., Al-Gazali L., Hill R.S., Donnai D., Black G.C., Bieth E., et al. Mutations in LRP2, which encodes the multiligand receptor megalin, cause Donnai-Barrow and facio-oculo-acoustico-renal syndromes. Nat Genet 2007, 39:957-959.
24. Pollock C.A., Poronnik P. Albumin transport and processing by the proximal tubule: physiology and pathophysiology. Curr Opin Nephrol Hypertens 2007, 16:359-364.
25. Birn H., Christensen E.I. Renal albumin absorption in physiology and pathology. Kidney Int 2006, 69:440-449.
26. Verroust P.J., Christensen E.I. Megalin and cubilin - the story of two multipurpose receptors unfolds. Nephrol Dial Transplant 2002, 17:1867-1871.
27. Lewington A.J., Arici M., Harris K.P., Brunskill N.J., Walls J. Modulation of the renin-angiotensin system in proteinuric renal disease: are there added benefits?. Nephrol Dial Transplant 2001, 16:885-888.
28. Caruso-Neves C., Kwon S.H., Guggino W.B. Albumin endocytosis in proximal tubule cells is modulated by angiotensin II through an AT2 receptor-mediated protein kinase B activation. Proc Natl Acad Sci U S A 2005, 102:17513-17518.
29. Hosojima M., Sato H., Yamamoto K., Kaseda R., Soma T., Kobayashi A., et al. Regulation of megalin expression in cultured proximal tubule cells by angiotensin II type 1A receptor- and insulin-mediated signaling cross talk. Endocrinology 2009, 150:871-878.
30. Tojo A., Onozato M.L., Kurihara H., Sakai T., Goto A., Fujita T. Angiotensin II blockade restores albumin reabsorption in the proximal tubules of diabetic rats. Hypertens Res 2003, 26:413-419.
31. Ryan M.J., Johnson G., Kirk J., Fuerstenberg S.M., Zager R.A., Torok-Storb B. HK-2: an immortalized proximal tubule epithelial cell line from normal adult human kidney. Kidney Int 1994, 45:48-57.
32. Padiyar A, Bodziak KA, Hricik DE, Augustine JJ. Clinical Predictors of Proteinuria after Conversion to Sirolimus in Kidney Transplant Recipients. Am J Transplant.
33. Vollenbroker B., George B., Wolfgart M., Saleem M.A., Pavenstadt H., Weide T. mTOR regulates expression of slit diaphragm proteins and cytoskeleton structure in podocytes. Am J Physiol Ren Physiol 2009, 296:F418-F426.
34. Franz S., Regeniter A., Hopfer H., Mihatsch M., Dickenmann M. Tubular toxicity in sirolimus- and cyclosporine-based transplant immunosuppression strategies: an ancillary study from a randomized controlled trial. Am J Kidney Dis 2010, 55:335-343.
35. Mreich E., Coombes J.D., Rangan G.K. Sirolimus does not reduce receptor-mediated endocytosis of albumin in proximal tubule cells. Transplantation 2007, 83:105-107.
36. Christensen E.I., Birn H., Verroust P., Moestrup S.K. Membrane receptors for endocytosis in the renal proximal tubule. Int Rev Cytol 1998, 180:237-284.
37. Willnow T.E., Hilpert J., Armstrong S.A., Rohlmann A., Hammer R.E., Burns D.K., et al. Defective forebrain development in mice lacking gp330/megalin. Proc Natl Acad Sci U S A 1996, 93:8460-8464.
38. Verroust P.J., Kozyraki R. The roles of cubilin and megalin, two multiligand receptors, in proximal tubule function: possible implication in the progression of renal disease. Curr Opin Nephrol Hypertens 2001, 10:33-38.
39. Kristiansen M., Kozyraki R., Jacobsen C., Nexo E., Verroust P.J., Moestrup S.K. Molecular dissection of the intrinsic factor-vitamin B12 receptor, cubilin, discloses regions important for membrane association and ligand binding. J Biol Chem 1999, 274:20540-20544.
40. Aminoff M., Carter J.E., Chadwick R.B., Johnson C., Grasbeck R., Abdelaal M.A., et al. Mutations in CUBN, encoding the intrinsic factor-vitamin B12 receptor, cubilin, cause hereditary megaloblastic anaemia 1. Nat Genet 1999, 21:309-313.
41. Gekle M., Knaus P., Nielsen R., Mildenberger S., Freudinger R., Wohlfarth V., et al. Transforming growth factor-beta1 reduces megalin- and cubilin-mediated endocytosis of albumin in proximal-tubule-derived opossum kidney cells. J Physiol 2003, 552:471-481.
42. Rangan G.K. Sirolimus-associated proteinuria and renal dysfunction. Drug Saf 2006, 29:1153-1161.
43. Ruggenenti P., Perna A., Gherardi G., Garini G., Zoccali C., Salvadori M., et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999, 354:359-364.
44. Jafar T.H., Stark P.C., Schmid C.H., Landa M., Maschio G., de Jong P.E., et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003, 139:244-252.
45. Bakris G.L., Weir M.R., DeQuattro V., McMahon F.G. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1998, 54:1283-1289.
46. Mogensen C.E., Neldam S., Tikkanen I., Oren S., Viskoper R., Watts R.W., et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. Bmj 2000, 321:1440-1444.
47. Russo D., Pisani A., Balletta M.M., De Nicola L., Savino F.A., Andreucci M., et al. Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis 1999, 33:851-856.